Nebenwirkungen · Docetaxel Kabi
DOCETAXEL KABI 20 mg/1 ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 15–16
HOS-214542 · Präparat HOS-155350
15 MedDRA system organ Very common adverse Common adverse reactions classes reactions Metabolism and nutrition Anorexia disorders Nervous system disorders Peripheral sensory neuropathy Peripheral motor neuropathy (G3/4: 0.8%) (G3/4: 2.5%) Cardiac disorders Arrhythmia (no severe) Vascular disorders Hypotension Gastrointestinal disorders Nausea (G3/4: 3.3%); Constipation Stomatitis (G3/4: 1.7%); Vomiting (G3/4: 0.8%); Diarrhoea (G3/4: 1.7%) Skin and subcutaneous tissue Alopecia; Nail disorders (severe: 0.8%) disorders Skin reaction (G3/4: 0.8%) Musculoskeletal and Myalgia connective tissue disorders General disorders and Asthenia (severe: 12.4%); administration site conditions Fluid retention (severe: 0.8%);Pain Investigations G3/4 Blood bilirubin increased (< 2%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage 3e2504fec1e261243339cca3747fa1899c2c6eabb9e77bcc3438571bd536d376 · Zeichen 10860–12257 im Abschnitt